What are the most common mistakes with FGL?
The most common FGL mistakes are treating it as a defined nootropic with established protocols; long cycles without safety data. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for FGL is limited.
Common FGL mistakes
- Treating it as a defined nootropic with established protocols
- Long cycles without safety data
References
- A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo — Skibo GG, Lushnikova IV, Voronin KY, Dmitrieva O, Novikova T, Klementiev B, Vaudano E, Berezin VA, Bock E. European Journal of Neuroscience, 2005
- The neural cell adhesion molecule-derived peptide, FGL, attenuates lipopolysaccharide-induced changes in glia in a CD200-dependent manner — Cox FF, Berezin V, Bock E, Lynch MA. Neuroscience, 2013
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on FGL
Last updated 2026-06-15.